DJIA 16,409.69 147.13 0.90%
NASDAQ 4,084.74 50.58 1.25%
S&P 500 1,861.35 18.37 1.00%
market minute promo

Isis Pharmaceuticals

NASDAQ: ISIS

34.55 1.56 (4.73%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ISIS $34.55 4.73%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $33.54
Previous Close $32.99
Daily Range $32.61 - $35.00
52-Week Range $18.27 - $62.66
Market Cap $4.1B
P/E Ratio -59.98
Dividend (Yield) $0.00 (0.0%)
Volume 2,278,003
Average Daily Volume 2,152,497
Current FY EPS -$0.70

Sector

Healthcare

Industry

Drugs

Isis Pharmaceuticals (ISIS) Description

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases. Website: http://www.isispharm.com/

News & Commentary Rss Feed

Which Themes in Biotech Today are Bankable?

RNAi is a new biotech technology investors need to watch.

Aegerion Shares Up on Study Initiation - Analyst Blog

PTC Therapeutics Looks Like A High-Risk Play On Rare Diseases

In A Shaky Biotech Market, Alnylam's Prospects Are Getting Stronger

Isis Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ISIS

Cramer: Keep an Eye on Celgene (CELG), Gilead (GILD), Isis Pharmaceuticals (ISIS) and Seattle Geneti

Cramer: Keep an Eye on Celgene (CELG), Gilead (GILD), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN)

Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx

BBH, ALKS, BMRN, ISIS: Large Outflows Detected at ETF

Jim Cramer: Wait for the All-Clear

'Mad Money' Lightning Round: Stay Far Away From Boardwalk Partners

EARLIER: Isis Announces Antisense Targeting of HBV Produces Dose-Dependent Reductions in Hepatitis B

EARLIER: Isis Announces Antisense Targeting of HBV Produces Dose-Dependent Reductions in Hepatitis B Virus in an Animal Model of HBV

See More ISIS News...

ISIS's Top Competitors

ISIS $34.55 (4.73%)
Current stock: ISIS
AMGN $115.49 (0.43%)
Current stock: AMGN
GILD $69.25 (1.58%)
Current stock: GILD
BIIB $291.48 (2.10%)
Current stock: BIIB